Generation Bio Co (GBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Generation Bio Co stock (GBIO) is currently trading at $5.34. Generation Bio Co PS ratio (Price-to-Sales) is 2.36. Analyst consensus price target for GBIO is $5.25. WallStSmart rates GBIO as Sell.
- GBIO PE ratio analysis and historical PE chart
- GBIO PS ratio (Price-to-Sales) history and trend
- GBIO intrinsic value — DCF, Graham Number, EPV models
- GBIO stock price prediction 2025 2026 2027 2028 2029 2030
- GBIO fair value vs current price
- GBIO insider transactions and insider buying
- Is GBIO undervalued or overvalued?
- Generation Bio Co financial analysis — revenue, earnings, cash flow
- GBIO Piotroski F-Score and Altman Z-Score
- GBIO analyst price target and Smart Rating
Generation Bio Co
📊 No data available
Try selecting a different time range
Smart Analysis
Generation Bio Co (GBIO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Generation Bio Co (GBIO) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
66.07% held by institutions, strong professional interest
Supporting Valuation Data
Generation Bio Co (GBIO) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -78.90%, a shrinking business
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.36x sales
Supporting Valuation Data
Generation Bio Co (GBIO) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.71) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.36) suggest expensive pricing. Growth concerns include Revenue Growth at -78.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -80.80%, Operating Margin at -2020.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -80.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -78.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GBIO's Price-to-Sales ratio of 2.36x trades at a deep discount to its historical average of 1449.27x (23th percentile). The current valuation is 100% below its historical high of 8097.43x set in Nov 2020, and 2257% above its historical low of 0.1x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Generation Bio Co (GBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Generation Bio Co operates as a stable business with moderate growth and solid fundamentals. Revenue reached 15M with 79% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 92% of revenue (14M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 79% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -53M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.01, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Generation Bio Co.
Bottom Line
Generation Bio Co offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Generation Bio Co(GBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Generation Bio Co., a genetic drug company, develops gene therapies for the treatment of rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts.